On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017

Design: Official national criminal records were cross linked with all patients who started opioid mainte- nance treatment in Norway from 1997-2003 (n=3221), including patients from

Aims To present the substances and their concentrations detected postmortem in patients receiving opioid agonist treat- ment (OAT) strati fi ed by cause of death, estimate the

Aim: We aimed to describe opioid maintenance treatment (OMT) to pregnant women in Norway and study the background characteristics of the pregnant women compared to the

Characteristics of individuals who received opioid substitution treatment and were treated for hepatitis C virus (HCV) infection between 2004 and 2013 (n = 943), strati- fied

Increase in hepatitis A in tourists from Denmark, England, Germany, the Netherlands, Norway and Sweden returning from Egypt, November 2012 to March 2013.. Available

The first aim was to study the treatment uptake of chronic hepatitis C (HCV) among people enrolled in opioid agonist therapy (OAT), secondly to assess symptoms of mental

The proportion of patients who received ADHD medi- cation increased in the inclusion period. Nevertheless, the dispensation rates were still in the lower range of what was expected.

In the period 2013 to 2017, a steady proportion of the Norwegian OAT population received at least one pre- scription of a benzodiazepine or z-hypnotic. Further- more, the number